FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Private fund managers “recycle” capital — i.e., reinvest capital that would otherwise be returned to investors or to recall distributions already ...

On February 13, the House Budget Committee, voting 21-16 along party lines (Republicans in favor and Democrats opposed), passed a 2025 ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...